Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring psychedelic compound found in certain cacti.
Earlier this month, XPhyto announced a new agreement with Applied Pharmaceutical Innovation over the synthesis of pharmaceutical-grade psychedelic compounds
XPhyto Therapeutics Corp (CSE:XPHYU) (OTCQB:XPHYF) (FRA:4XT) revealed on Wednesday that it has added the production of mescaline to its psychedelic medicine programs.
Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring psychedelic compound found in certain cacti and has been anecdotally found to show promise for treating addiction and depression.
READ: XPhyto Therapeutics strikes agreement to produce pharmaceutical-grade psychedelic compounds
Earlier this month, Vancouver-based XPhyto announced a new agreement with Applied Pharmaceutical Innovation over the synthesis of pharmaceutical-grade psychedelic compounds.
“In addition to our European-based psilocybin biotechnology production, the company has now expanded its portfolio of psychedelic compounds to include mescaline,” said Hugh Rogers, XPhyto’s CEO, in a statement.
“Our goal is to develop industrial-scale production processes for the wholesale market and for incorporation into XPhyto’s thin-film drug delivery platforms.
“We see a significant market opportunity in the production of pharmaceutical mescaline and the standardization of dosage formulations with precise, predictable and efficient drug delivery for clinical study and therapeutic use.”
XPhyto Therapeutics describes itself as a ‘bioscience accelerator’ focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities,
On November 3 last year, it also announced an agreement with a leading German university for the exclusive development of a proprietary biotechnology process for the industrial manufacture of pharmaceutical-grade psilocybin.
Contact the author at giles@proactiveinvestors.com
Leave A Comment
You must be logged in to post a comment.